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Dobutamine is a widely prescribed form of inotropic support for
patients with heart failure, but infusion thereof has been associated
with hypersensitivity reactions, namely eosinophilia or eosinophilic
myocarditis.1e5 However, it remains unclear whether the true
culprit is dobutamine per se or its excipient, sulﬁte.6,7 We report a
case of recurrent hypereosinophilia with a skin rash that developed
during dobutamine infusion. We used an in vitro ﬂow cytometric
assay to show that the hypersensitivity was attributable to sulﬁte.
Case
A 74-year-old male presented to the allergy clinic with hypereo-
sinophilia (2955/mm3) and a generalized morbiliform rash. He hadFig. 1. Clinical courses of blood eosinophil c
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had been under supportivemanagement that included dobutamine
infusion (Fig. 1). He had multiple comorbid illnesses, including dia-
betes mellitus, three-vessel disease, and chronic obstructive pul-
monary disease. His initial problems on admission, including
dyspnea and edema, gradually improved with supportive manage-
ment. However, his blood eosinophil count began to increase on
hospital day (HD) #5, and a rash developed on HD#12. No fever
was evident. Laboratory markers of liver and kidney function
were normal. The patient's total serum IgE level was 198 IU/mL.
He did not have elevated IgG antibodies against common parasites.
We reviewed his prior medical records and found that he had
experienced two similar episodes of eosinophilia and/or a rash
during two recent hospitalizations necessitated by aggravated
heart failure, but no eosinophilia was evident during outpatient
follow-ups (Fig. 1). The ﬁrst episode occurred 2 years prior; his
blood eosinophil count increased from 87/mm3 on HD#1 to 821/
mm3 on HD#16. He received dobutamine infusions during thatounts, rash, and dobutamine exposure.
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months prior, where his blood eosinophil count increased from
36/mm3 on HD#1 to 2132/mm3 on HD#7, and a generalized mor-
biliform rash developed on HD#9. Dobutamine infusion was
stopped on HD#8, and the eosinophilia and rash graduallyFig. 2. In vitro ﬂow cytometric measurements of interferon-g expression in CD8þ T lymp
example showing our ﬂow cytometric measurement in CD8þ T lymphocytes were measure
or sodium metabisulﬁte (right column), respectively. (B) Bar graphs showing stimulation ind
with the drug stimulation compared to cultures without the stimulation. Data are expresse
unteers and the patient was statistically signiﬁcant (*p < 0.05 by the Mann-Whitney U tesimproved (eosinophil count was 572/mm3 on discharge day,
HD#18).
Based on this history, we suspected that his current hypereosi-
nophilia and rash were attributable to dobutamine hypersensitiv-
ity. We stopped the dobutamine infusion and prescribed ahocytes after dobutamine or sodium metabisulﬁte stimulation. (A) A representative
d after 72 hours of in vitro stimulation with diluted dobutamine pre-mix (mid-column)
ex (SI), which indicates the fold increase in interferon-g expression in in vitro cultures
d as mean ± standard errors of means. The difference in SI between three healthy vol-
t). Conc, concentration; SI, stimulation index.
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rash and eosinophil count gradually improved (eosinophil count
fell from a peak of 6154/mm3 on HD#17 to 746/mm3 on HD#23);
he was discharged on HD#23.
To conﬁrm that dobutamine had caused the problems described
above, we performed an in vitro cell stimulation assay. We obtained
peripheral blood mononuclear cells (PBMCs) 4 weeks after discon-
tinuation of systemic corticosteroid therapy. We used ﬂow cytome-
try to measure the in vitro interferon-g (IFN-g) expression levels in
T lymphocytes; the method was a slight modiﬁcation of that re-
ported earlier.8 We ﬁrst tested the injectable form of dobutamine
(the agent administered during development of hypersensitivity;
Dobutamine HCl Pre-mix Injection; 500 mg dobutamine and
52 mg sodium metabisulﬁte in 5% [w/v] dextrose; 250 mL). We
also examined the in vitro response to sodiummetabisulﬁte (Sigma),
because earlier expert reports suggested that sulﬁte hypersensitivity
might be in play during dobutamine-associated eosinophilia or
eosinophilic myocarditis.1,2,9 Brieﬂy, PBMCs were isolated from
whole blood by centrifugation through Ficoll-Paque-Plus solution
(GE Healthcare). The cells were suspended to a concentration of
5  106/mL in RPMI 1640 medium supplemented with 10% (v/v)
heat-inactivated fetal bovine serum. Next, 0.1 mL amounts of cell
suspensionwere added to thewells of a 96-well tissue culture plate.
Diluted dobutamine pre-mix (in 0.1 mL culture medium) or sodium
metabisulﬁte (also in 0.1 mL culture medium) was added to the
wells. The ﬁnal concentrations were determined as 2 mg/ml
(1:1000 dilution) for dobutamine, and 0.208 mg/ml (1:1000 dilution)
for sodium metabisulﬁte, respectively; cytotoxic effects were
observed at concentrations higher than 2.08 mg/ml (1:100 dilution)
for sodium metabisulﬁte. The plates were incubated for 3 days
(37 C, 5% [v/v] CO2, 100% humidity).
For each drug stimulation, IFN-g expression levels in CD8þ T
lymphocytes were measured by ﬂow cytometry (Fig. 2A). Stimula-
tion index (SI) was calculated as ‘IFN-g expression levels with drug
stimulation divided by the levels at baseline’. All measurements
were done in triplicate. IFN-g expression levels increased compared
to the baseline when CD8þ T lymphocytes were stimulated with
the dobutamine pre-mix (SI 1.5). However, IFN-g expression levels
also increased with sodium metabisulﬁte stimulation (SI 1.7). Such
responses were not observed in three healthy volunteers. The dif-
ference in SI between the patient and healthy volunteers was statis-
tically signiﬁcant (Fig. 2B). Thus, we diagnosed our patient with
sulﬁte hypersensitivity.
Sulﬁte is commonly found in drugs and food products, and has
been suggested to be an unsuspected cause of drug or food hyper-
sensitivity.10 As suggested in earlier cardiology articles, sulﬁte has
also been suspected to trigger hypersensitivity reactions in patients
receiving dobutamine infusions.1,2,9 However, this possibility has
never been directly tested. A recent case report on a patient with
eosinophilic endomyocarditis showed that the dobutamine prepa-
ration used (which included sulﬁte) stimulated lymphocytes, but
did not separately explore any possible effect of sulﬁte.11 Our pre-
sent ﬁnding suggests that it is important to determine the propor-
tion of patients who develop sulﬁte hypersensitivity when infused
with dobutamine preparations.
It is unclear whether our patient developed eosinophilic
myocarditis caused by sulﬁte hypersensitivity. However, as his
heart failure symptoms improved during dobutamine infusion
and supportive management, we speculate that eosinophilic
myocarditis was probably not in play. We observed no other rele-
vant systemic sign or symptom, and thus concluded that the sulﬁte
hypersensitivity, presenting with hypereosinophilia and a skin
rash, did not meet the criteria for DRESS syndrome.
In vitro assays yield evidence of (only) “immunological sensitiza-
tion”; such tests cannot prove that sulﬁte hypersensitivity actuallytriggers eosinophilia and/or rash. However, the recurrent episodes
of hypersensitivity developing upon dobutamine infusion and the
positive in vitro response to sulﬁte strongly support a diagnosis of
sulﬁte hypersensitivity in the present case.
We measured IFN-g levels as the marker for acute phase reac-
tion of CD8þ T lymphocytes to drug stimulation. In the literature,
in vitro IFN-g assays have been frequently used as the rapid and
relatively convenient diagnostic tools to determine T-cell mediated
sensitization to drugs in patients with delayed-type drug hypersen-
sitivity.12,13 However, we agree that further assays for eosinophilo-
poietic cytokines, such as IL-5, should be necessary to detect the
intrinsic nature of this clinical syndrome. Also, accumulation of
cases is needed to clarify the mechanism of sulﬁte hypersensitivity.
In conclusion, this is the ﬁrst case report on a patient exhibiting
dobutamine infusion-related hypersensitivity to include in vitro
immunological assessment of sulﬁte hypersensitivity. Clinical aller-
gists need to be aware that dobutamine infusion may trigger hyper-
sensitivity reactions (eosinophilia and/or rash). Also, the proportion
of patients who are in fact hypersensitive to sulﬁte, should be
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